BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
Total Valuation
BridgeBio Oncology Therapeutics has a market cap or net worth of $710.69M. The enterprise value is $339.77M.
Market Cap$710.69M
Enterprise Value$339.77M
Share Statistics
BridgeBio Oncology Therapeutics has 80,032,820 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding80,032,820
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BridgeBio Oncology Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -35.23%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-35.23%
Return on Capital Employed (ROCE)-0.35
Revenue Per Employee0.00
Profits Per Employee-2.16M
Employee Count62
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BridgeBio Oncology Therapeutics is ―. BridgeBio Oncology Therapeutics’s PEG ratio is 0.00281.
PE Ratio―
PS Ratio0.00
PB Ratio0.95
Price to Fair Value0.95
Price to FCF-3.41
Price to Operating Cash Flow-2.91
PEG Ratio0.00281
Income Statement
In the last 12 months, BridgeBio Oncology Therapeutics had revenue of 0.00 and earned -134.04M in profits. Earnings per share was -4.30.
Revenue0.00
Gross Profit-610.00K
Operating Income-145.82M
Pretax Income-134.04M
Net Income-134.04M
EBITDA-145.82M
Earnings Per Share (EPS)-4.30
Cash Flow
In the last 12 months, operating cash flow was -95.03M and capital expenditures -444.00K, giving a free cash flow of -95.47M billion.
Operating Cash Flow-95.03M
Free Cash Flow-95.47M
Free Cash Flow per Share-1.19
Dividends & Yields
BridgeBio Oncology Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.13
52-Week Price Change-21.42%
50-Day Moving Average10.55
200-Day Moving Average11.10
Relative Strength Index (RSI)39.69
Average Volume (3m)344.97K
Important Dates
BridgeBio Oncology Therapeutics upcoming earnings date is Mar 5, 2026, After Close (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 5, 2026
Ex-Dividend Date―
Financial Position
BridgeBio Oncology Therapeutics as a current ratio of 12.14, with Debt / Equity ratio of 0.67%
Current Ratio12.14
Quick Ratio12.14
Debt to Market Cap<0.01
Net Debt to EBITDA2.54
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BridgeBio Oncology Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BridgeBio Oncology Therapeutics EV to EBITDA ratio is -0.13, with an EV/FCF ratio of -0.17.
EV to Sales0.00
EV to EBITDA-0.13
EV to Free Cash Flow-0.17
EV to Operating Cash Flow-0.17
Balance Sheet
BridgeBio Oncology Therapeutics has $425.46M in cash and marketable securities with $2.77M in debt, giving a net cash position of $422.69M billion.
Cash & Marketable Securities$425.46M
Total Debt$2.77M
Net Cash$422.69M
Net Cash Per Share$5.28
Tangible Book Value Per Share$13.20
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for BridgeBio Oncology Therapeutics is $25.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$25.38
Price Target Upside101.55% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast―